MedCity Influencers

FDA Finally Unveils Risk Management Plan for ESAs

Nearly two years after a Food and Drug Administration advisory committee called for restrictions on the use of red blood cell-stimulating drugs in cancer patients (erythropoiesis-stimulating agents or ESAs), the agency Tuesday unveiled a stringent risk management plan that should further lower use of the drugs, which are already in freefall in cancer patients.